Stereotactic Body Radiotherapy for Patients with Lung Oligometastatic Disease: A Five-Year Systematic Review.
Fiche publication
Date publication
juillet 2021
Journal
Cancers
Auteurs
Membres identifiés du Cancéropôle Est :
Pr ANTONI Delphine, Pr NOEL Georges, Dr LE FEVRE Clara
Tous les auteurs :
Virbel G, Le Fèvre C, Noël G, Antoni D
Lien Pubmed
Résumé
For several years, oligometastatic disease has represented an intermediate state between localized disease accessible to local treatment and multimetastatic disease requiring systemic therapy. The lung represents one of the most common metastatic locations. Stereotactic body radiation therapy (SBRT) appears to be the treatment of choice for these patients. There are few data defining the place of radiotherapy and reporting outcome after SBRT in lung metastases. This 5-year review aimed to determine areas of SBRT usefulness and methods for the management of pulmonary metastasis in oligometastatic patients. A search for articles on PubMed allowed selection of the most relevant studies. Eighteen articles were selected according to pre-established criteria for this purpose. The analysis concludes that SBRT is an effective and safe treatment in selected patients when the disease remains localized from one to three organs.
Mots clés
lung, metastases, oligometastatic, stereotactic body radiotherapy
Référence
Cancers (Basel). 2021 Jul 20;13(14):